dc.contributor.author | Avrich, Erin | eng |
dc.contributor.author | Sulik, Sandra | eng |
dc.contributor.author | Nashelsky, Joan | eng |
dc.date.issued | 2006 | eng |
dc.description.abstract | Of the different strategies available for managing cervical intraepithelial neoplasia grade 1 (CIN1), testing for high-risk subtypes of the human papillomavirus (hr-HPV) DNA at 12 months has the highest sensitivity for predicting the development of CIN2 or CIN3 and leads to the lowest rate of referral to repeat colposcopy (TABLE 1). If the hr-HPV DNA test result is negative at 12 months, then the patient may return to routine cytology screening. If the hr-HPV DNA test result is positive, the patient should undergo repeat colposcopy. | eng |
dc.identifier.uri | http://hdl.handle.net/10355/3530 | eng |
dc.language | English | eng |
dc.publisher | Family Physicians Inquiries Network | eng |
dc.relation.ispartofcollection | Clinical Inquiries, 2006 (MU) | eng |
dc.relation.ispartofcommunity | University of Missouri--Columbia. School of Medicine. Department of Family and Community Medicine. Family Physicians Inquiries Network | eng |
dc.relation.ispartofseries | Journal of family practice, 55, no. 02 (February 2006) | eng |
dc.rights | OpenAccess. | eng |
dc.rights.license | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License. | eng |
dc.subject | human papillomavirus | eng |
dc.subject | cytology screening | eng |
dc.subject | cancer screening | eng |
dc.subject.lcsh | Papillomaviruses | eng |
dc.subject.lcsh | Colposcopy | eng |
dc.subject.lcsh | Cancer | eng |
dc.title | What is the appropriate management for a patient with CIN1 on colposcopy? | eng |
dc.type | Article | eng |